Tag Archives: Boris Peaker

Cowen & Co. Keeps a Buy Rating on Stemline Therapeutics Inc (STML)

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Stemline Therapeutics Inc (STML – Research Report). The company’s shares closed last Monday at $10.83. According to TipRanks.com, Peaker is a 3-star analyst with

Cowen & Co. Reaffirms Their Hold Rating on Ironwood Pharma (IRWD)

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Ironwood Pharma (IRWD – Research Report) today and set a price target of $12. The company’s shares closed last Monday at $9.65. According to TipRanks.com, Peaker is a 2-star

Cowen & Co. Sticks to Their Buy Rating for Trillium Therapeutics (TRIL)

In a report issued on August 13, Boris Peaker from Cowen & Co. maintained a Buy rating on Trillium Therapeutics (TRIL – Research Report). The company’s shares closed last Monday at $0.25, close to its 52-week low of $0.24. According

Cowen & Co. Reaffirms Their Buy Rating on Molecular Templates Inc (MTEM)

In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on Molecular Templates Inc (MTEM – Research Report). The company’s shares closed yesterday at $5.01. According to TipRanks.com, Peaker is a 3-star analyst with an

Cowen & Co. Reaffirms Their Buy Rating on Stemline Therapeutics Inc (STML)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Stemline Therapeutics Inc (STML – Research Report) today. The company’s shares closed on Friday at $14.86. According to TipRanks.com, Peaker is a 3-star analyst with an average return of

Cowen & Co. Keeps Their Hold Rating on Emergent Biosolutions (EBS)

In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Emergent Biosolutions (EBS – Research Report), with a price target of $60. The company’s shares closed yesterday at $44.19, close to its 52-week low